PsySonics develops immersive soundscapes specifically engineered for mental health clinicians and their patients undergoing psychedelic-assisted therapy with MDMA, Ketamine, and Psilocybin. This technology enhances the therapeutic experience by providing a continuous auditory environment that supports emotional processing, ensuring that the efficacy of treatment is maximized.
Funding
Funding not disclosed
Founders
Product
Problem
Patients undergoing psychedelic-assisted therapy (PAT) with substances like MDMA, ketamine, and psilocybin require a supportive and consistent auditory environment to facilitate emotional processing. Existing music playlists may lack the consistency and specific design needed to optimize the therapeutic experience.
Solution
PsySonics provides immersive, non-musical soundscapes designed to enhance mental health clinicians' psychedelic-assisted therapy sessions. These sound environments are engineered to support emotional processing and create a therapeutic sanctuary for patients. PsySonics' approach moves beyond conventional music playlists by offering a continuous, uninterrupted auditory experience tailored to the unique needs of PAT. The sounds are designed in collaboration with clinicians and are based on psychedelic research.
Target Audience
PsySonics targets mental health clinicians, therapists, and mental health institutions providing psychedelic-assisted therapy to patients.
Features
- Immersive, nature-based soundscapes specifically engineered for psychedelic-assisted therapy
- Non-musical audio environments designed to support emotional processing during PAT sessions
- Developed in partnership with mental health clinicians
- Designed to provide a consistent and uninterrupted auditory experience
- Optimized for use with MDMA, ketamine, and psilocybin treatments